Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease
Ruxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis. In preclinical and retrospective clinical studies, use of ruxolitinib was shown to reduce graft-versus-host-disease (GVHD) in allograft...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2018/4539757 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563555061202944 |
|---|---|
| author | Allison P. Watson Claudio G. Brunstein Shernan G. Holtan |
| author_facet | Allison P. Watson Claudio G. Brunstein Shernan G. Holtan |
| author_sort | Allison P. Watson |
| collection | DOAJ |
| description | Ruxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis. In preclinical and retrospective clinical studies, use of ruxolitinib was shown to reduce graft-versus-host-disease (GVHD) in allograft recipients with moderate/severe corticosteroid-dependent or refractory chronic GVHD. While the exact mechanism for action in GVHD is not yet fully understood, prospective studies are ongoing and some patients are receiving ruxolitinib in the setting of steroid refractory GVHD. Although ruxolitinib is generally well tolerated, here we describe a case involving a 50-year-old man with acute myeloid leukemia and chronic GVHD who experienced life-threatening hypertriglyceridemia associated with concomitant use of sirolimus and ruxolitinib for GVHD. This case report highlights the importance of vigilance for severe side effects in novel immunosuppressive drug combinations. |
| format | Article |
| id | doaj-art-4fd6d588feee4a43a6267dccd6fcb434 |
| institution | Kabale University |
| issn | 2090-6943 2090-6951 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Transplantation |
| spelling | doaj-art-4fd6d588feee4a43a6267dccd6fcb4342025-02-03T01:13:08ZengWileyCase Reports in Transplantation2090-69432090-69512018-01-01201810.1155/2018/45397574539757Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host DiseaseAllison P. Watson0Claudio G. Brunstein1Shernan G. Holtan2Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, USABlood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, USABlood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, USARuxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis. In preclinical and retrospective clinical studies, use of ruxolitinib was shown to reduce graft-versus-host-disease (GVHD) in allograft recipients with moderate/severe corticosteroid-dependent or refractory chronic GVHD. While the exact mechanism for action in GVHD is not yet fully understood, prospective studies are ongoing and some patients are receiving ruxolitinib in the setting of steroid refractory GVHD. Although ruxolitinib is generally well tolerated, here we describe a case involving a 50-year-old man with acute myeloid leukemia and chronic GVHD who experienced life-threatening hypertriglyceridemia associated with concomitant use of sirolimus and ruxolitinib for GVHD. This case report highlights the importance of vigilance for severe side effects in novel immunosuppressive drug combinations.http://dx.doi.org/10.1155/2018/4539757 |
| spellingShingle | Allison P. Watson Claudio G. Brunstein Shernan G. Holtan Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease Case Reports in Transplantation |
| title | Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease |
| title_full | Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease |
| title_fullStr | Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease |
| title_full_unstemmed | Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease |
| title_short | Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease |
| title_sort | life threatening hypertriglyceridemia in a patient on ruxolitinib and sirolimus for chronic graft versus host disease |
| url | http://dx.doi.org/10.1155/2018/4539757 |
| work_keys_str_mv | AT allisonpwatson lifethreateninghypertriglyceridemiainapatientonruxolitinibandsirolimusforchronicgraftversushostdisease AT claudiogbrunstein lifethreateninghypertriglyceridemiainapatientonruxolitinibandsirolimusforchronicgraftversushostdisease AT shernangholtan lifethreateninghypertriglyceridemiainapatientonruxolitinibandsirolimusforchronicgraftversushostdisease |